ArticlePloS one2019
A snapshot of antimicrobial resistance in Mexico. Results from 47 centers from 20 states during a six-month period.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Global prevalence of macrolide-resistantFrontiers in microbiology · 2025Pooled it
- Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates obtained from patients treated in a paediatric hospital in Mexico.Scientific reports · 2026Article
- Comparative genomics of methicillin-resistant and -susceptibleMicrobiology spectrum · 2026Article
- The threat of multidrug-resistant microorganisms: active surveillance of key antimicrobial resistant pathogens in 2025 - a report from the INVIFAR network.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Prevalence and antimicrobial resistance ofJournal of preventive medicine and hygiene · 2026Article
- Trends, Seasonality, and the Impact of COVID-19 on ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Resistance Landscape and Clonal Dynamics of ESKAPE Pathogens in Bloodstream Infections: A Multicenter Study from Mexico.Pathogens (Basel, Switzerland) · 2025Article
- Clonal Dissemination of Pandrug-ResistantInternational journal of molecular sciences · 2025Article
- Molecular Characterization of Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Resistance - The 'Real' Pandemic We Are Unaware Of, Yet Nearby.Journal of Korean medical science · 2025Review
- A Landscaping Assessment and Call-to-Action to Improve Access to Novel Reserve Antibiotics in 14 Low- and Middle-Income Countries.Public health challenges · 2024Article
- Article
- Antimicrobial Resistance and Antibiotic Consumption in a Secondary Care Hospital in Mexico.Antibiotics (Basel, Switzerland) · 2024Article
- Antibiotic resistance of ESKAPE group-microorganisms in health institutions from Hermosillo and Ciudad Obregón, Sonora, México.Frontiers in cellular and infection microbiology · 2024Observational
- Interesting Cytokine Profile Caused by Clinical Strains ofInternational journal of microbiology · 2024Article
- Active Surveillance of Antimicrobial Resistance and Carbapenemase-Encoding Genes According to Sites of Care and Age Groups in Mexico: Results from the INVIFAR Network.Pathogens (Basel, Switzerland) · 2023Article
- Isolation and Identification of Multidrug-ResistantPathogens (Basel, Switzerland) · 2023Article
- Comparison of Lateral Flow Immunochromatography and Phenotypic Assays to PCR for the Detection of Carbapenemase-Producing Gram-Negative Bacteria, a Multicenter Experience in Mexico.Antibiotics (Basel, Switzerland) · 2023Article
- Article
- High Frequency of Antibiotic Resistance Genes (ARGs) in the Lerma River Basin, Mexico.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 19 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe aimed to assess the resistance rates of antimicrobial-resistant, in bacterial pathogens of epidemiological importance in 47 Mexican centers. MATERIAL AND
methodsIn this retrospective study, we included a stratified sample of 47 centers, covering 20 Mexican states. Selected isolates considered as potential causatives of disease collected over a 6-month period were included. Laboratories employed their usual methods to perform microbiological studies. The results were deposited into a database and analyzed with the WHONET 5.6 software.
resultsIn this 6-month study, a total of 22,943 strains were included. Regarding Gram-negatives, carbapenem resistance was detected in ≤ 3% in Escherichia coli, 12.5% in Klebsiella sp. and Enterobacter sp., and up to 40% in Pseudomonas aeruginosa; in the latter, the resistance rate for piperacillin-tazobactam (TZP) was as high as 19.1%. In Acinetobacter sp., resistance rates for cefepime, ciprofloxacin, meropenem, and TZP were higher than 50%. Regarding Gram-positives, methicillin resistance in Staphylococcus aureus (MRSA) was as high as 21.4%, and vancomycin (VAN) resistance reached up to 21% in Enterococcus faecium. Acinetobacter sp. presented the highest multidrug resistance (53%) followed by Klebsiella sp. (22.6%) and E. coli (19.4%).
conclusionThe multidrug resistance of Acinetobacter sp., Klebsiella sp. and E. coli and the carbapenem resistance in specific groups of enterobacteria deserve special attention in Mexico. Vancomycin-resistant enterococci (VRE) and MRSA are common in our hospitals. Our results present valuable information for the implementation of measures to control drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.